

Clinical interpretation: ?Evidence is not yet sufficient to conclude that resmetirom prevents cirrhosis, hepatic decompensation, transplantation, liver cancer, cardiovascular events, or mortality. Not a substitute for metabolic management: It is indicated with diet and exercise, while diabetes, obesity, hypertension, and dyslipidemia still require optimized management. Lipid benefit: The LDL-C reduction may be particularly advantageous because many patients with MASH have substantial cardiometabolic risk. No established hard-outcome benefit yet: Current approvals are based on surrogate histologic endpoints. MASH resolution: Absolute benefit was approximately 16–20 percentage points beyond placebo. Fibrosis regression: Absolute benefit was approximately 10–12 percentage points beyond placebo.????